<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564590</url>
  </required_header>
  <id_info>
    <org_study_id>004548</org_study_id>
    <nct_id>NCT00564590</nct_id>
  </id_info>
  <brief_title>SThe Effects of Melatonin on GERD Symptoms</brief_title>
  <official_title>The Effects of Melatonin on GERD Symptoms and Esophageal Acid Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that melatonin as compared to PPI and to placebo, improves GERD symptoms by&#xD;
      decreasing esophageal acid exposure and esophageal acid sensitivity in GERD. We hypothesize&#xD;
      that melatonin as compared to PPI and to placebo reduce the frequency and duration of&#xD;
      transient lower esophageal sphincter relaxations (TLESRs). In addition we hypothesize that&#xD;
      melatonin as compared to PPI and to placebo improves quality of life and quality of sleep of&#xD;
      GERD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Gastroesophageal reflux disease (GERD) is a chronic, persistent and common&#xD;
      medical problem. The standard of care for GERD includes chronic administration of&#xD;
      acid-suppressive drugs. However, clinical failure in GERD is increasingly reported.&#xD;
&#xD;
      Aim: To determine the efficacy of treatment with melatonin as compared to standard dose&#xD;
      proton pump inhibitor (PPI) as compared to placebo in patients with GERD.&#xD;
&#xD;
      Study objectives: [1] To compare the degree of GERD symptoms improvement and esophageal acid&#xD;
      sensitivity before and after treatment. [2] To determine the effect of treatment on the %&#xD;
      total, upright and supine time pH &lt;4 using 24-hour esophageal pH monitoring. [3] To determine&#xD;
      the effect of treatment on frequency and duration of lower esophageal sphincter relaxation.&#xD;
      [4] To compare the quality of life and quality of sleep in GERD patients before and after&#xD;
      treatment.&#xD;
&#xD;
      Methods: This is a randomized, double blind, parallel groups study of 150 patients with GERD.&#xD;
      Patients with classic heartburn symptoms (heartburn and/or regurgitation) and normal upper&#xD;
      endoscopy from the gastroenterology department at Rabin Medical Center will be enrolled into&#xD;
      the study. At baseline, all enrolled patients will have 24-hour esophageal pH monitoring and&#xD;
      a modified acid perfusion test to assess the extent of distal esophageal acid exposure and&#xD;
      esophageal acid sensitivity, respectively. Patients will be evaluated by a demographics&#xD;
      questionnaire, the GERD Symptom Questionnaire, the Quality of Sleep questionnaire and the&#xD;
      SF-36. Baseline urinary excretion of the main melatonin metabolite, 6-sulfatoxymelatonin&#xD;
      (6SMT) will be assessed in all subjects at baseline. Patients will be randomized to either&#xD;
      melatonin or standard dose PPI or placebo over a period of 4 weeks. In addition patients will&#xD;
      fill a diary on a daily basis that documents severity and frequency of GERD-related symptoms.&#xD;
      Symptom score (frequency x severity) will be calculated for previous 7 days at baseline and&#xD;
      at the end of treatment in all groups. After 4 weeks of treatment, patients will undergo a&#xD;
      second 24-hour esophageal pH monitoring, a modified acid perfusion test and will complete the&#xD;
      GERD Symptom Questionnaire, the Quality of Sleep Questionnaire and the SF-36.&#xD;
&#xD;
      Implications: This study will determine if melatonin decreases GERD symptoms, acid esophageal&#xD;
      exposure and improves quality of life and sleep in patients with GERD. Furthermore, if there&#xD;
      will be a significant clinical response to melatonin it will be possible to add this compound&#xD;
      to the treatment armamentum of GERD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study will test the efficacy of melatonin (10 mg once a day) as compared to standard dose PPI (omeprazole 20 mg once a day) and placebo on different subjective and objective parameters of 150 patients with GERD.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of melatonin versus standard-dose PPI versus placebo on frequency and duration of TLESRs.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole 20 mg once a day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once a day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>4 mg of Melatonin once a day for 3 months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>omeprazole 20 mg once a day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Omepradex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once a day</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Ages 18-75.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  GERD symptoms at least twice a week for the last three months.&#xD;
&#xD;
          -  Able to read, understand and complete study questionnaires and diary&#xD;
&#xD;
          -  Understand the study procedures and sign written informed consent.&#xD;
&#xD;
          -  Able to comply with all study requirements.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Subjects with erosive esophagitis (EE), Barrett's esophagus (BE) and esophageal&#xD;
             stricture or adenocarcinoma on upper endoscopy.&#xD;
&#xD;
          -  Subjects with previous upper gastrointestinal surgery.&#xD;
&#xD;
          -  Subjects with clinically significant medical conditions (cardiovascular, respiratory,&#xD;
             renal, hepatic, hematologic, endocrine, neurologic and psychiatric); examples as&#xD;
             follows: liver cirrhosis, severe COPD, severe renal failure, severe heart failure,&#xD;
             active malignancy.&#xD;
&#xD;
          -  Subjects requiring narcotics (morphine, methadone, etc.).&#xD;
&#xD;
          -  Subjects requiring melatonin&#xD;
&#xD;
          -  Subjects with diabetes, scleroderma and neuromuscular disorders.&#xD;
&#xD;
          -  Lactating or pregnant women.&#xD;
&#xD;
          -  Subjects with an unrecognized lifestyle such as shift workers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ram M Dickman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ram M Dickman, MD</last_name>
    <phone>03:9377236</phone>
    <email>dickmanr@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tami Lederfine</last_name>
    <phone>03:9377040</phone>
    <email>Tamila@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ram M Dickman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Pereira Rde S. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res. 2006 Oct;41(3):195-200.</citation>
    <PMID>16948779</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2007</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

